Letters to the Editor

Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma

UKE, Department of Pediatric Hematology and Oncology, Hamburg
Hannover Medical School, Clinic for Pediatric Hematology and Oncology, Hannover
St. Anna Children’s Hospital, Medical University of Vienna, Department of Pediatric Hematology and Oncology, Vienna
Charles University and University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic
Hannover Medical School, Clinic for Pediatric Hematology and Oncology, Hannover
University of Gießen, Pediatric Hematology and Oncology, Gießen
University Medical Center Göttingen, Division of Pediatric Hematology and Oncology, Göttingen
Children's University Hospital Tübingen, Department of General Pediatrics and Pediatric Hematology/Oncology, Tübingen
University-Hospital of Münster, Pediatric Hematology and Oncology, Münster
Clinical Institute of Pathology, Medical University of Vienna, Vienna
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel
University-Hospital of Münster, Pediatric Hematology and Oncology, Münster
UKE, Department of Pediatric Hematology and Oncology, Hamburg
Haematologica Early view Sep 9, 2021 https://doi.org/10.3324/haematol.2021.278971